From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

The curse of Roby Zomer strikes again – the man with the reverse Midas touch

By Tom Winnifrith | Friday 15 March 2024


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


The downfall of MGC Pharmaceuticals (MXC) has been well documented on this website since I published a detailed dossier 18 months ago when it was valued at £70million. Those who backed its founder Roby Zomer rather than my analysis have lost 99% of their moolah. But MGC looks like a great British success compared to Zomer’s other effort, Graft Polymer (GPL), floated at 21.5p less than two years ago, its shares are just 0.16p after another disaster today.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Thursday »

Cat_Fixing_Lightbulb

Bearcast issue update: all should be well

 

ORCP

Oracle Power: Cynical Foul

Time left: 23:52:36